Hypofractionated stereotactic body radiation therapy for elderly patients with stage IIB-IV nonsmall cell lung cancer who are ineligible for or refuse other treatment modalities

Sana D Karam, Zachary D Horne, Robert L Hong, Don McRae, David Duhamel, Nadim M Nasr, Sana D Karam, Zachary D Horne, Robert L Hong, Don McRae, David Duhamel, Nadim M Nasr

Abstract

Objective: In elderly patients with stage IIB-IV nonsmall cell lung cancer who cannot tolerate chemotherapy, conventionally fractionated radiotherapy is the treatment of choice. We present our experience with hypofractionated stereotactic body radiation therapy (SBRT) in the treatment of this patient population.

Methods: Thirty-three patients with a median age of 80 years treated with fractionated SBRT were retrospectively analyzed. Most patients were smokers and had preexisting lung disease and either refused treatment or were ineligible. A median prescribed dose of 40 Gy was delivered to the prescription isodose line over a median of five treatments. The majority of patients (70%) did not receive chemotherapy.

Results: With a median follow-up of 9 months (range: 4-40 months), the actuarial median overall survival (OS) and progression-free survival were 12 months for both. One year actuarial survival outcomes were 75%, 58%, 44%, and 48% for local control, regional control, progression-free survival, and OS, respectively. Increased volume of disease was a statistically significant predictor of worse OS. Three patients developed a grade 1 cough that peaked 3 weeks after treatment and resolved within 1 month. One patient developed grade 1 tracheal mucositis and three patients developed grade 1 pneumonitis. Both resolved 6 weeks after treatment. Three patients died within the first month of treatment, but the cause of death did not appear to be related to the treatment.

Conclusion: Hypofractionated SBRT is a relatively safe and convenient treatment option for elderly patients with inoperable stage IIB-IV nonsmall cell lung cancer. However, given the small sample size and the heterogeneity of the patient population, larger studies are needed before adopting this treatment option into clinical practice.

Keywords: CyberKnife; chemotherapy; nodal; stage IIB; stage IIIA; stage IV; stereotactic body radiation therapy.

Conflict of interest statement

Disclosure The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Survival outcomes of all patients with early-stage lung cancer (number =33). Notes: (A) Local control; (B) regional control; (C) progression-free survival; (D) overall survival.
Figure 2
Figure 2
Overall survival for all patients by volume.

References

    1. McCloskey P, Balduyck B, Van Schil PE, Faivre-Finn C, O’Brien M. Radical treatment of non-small cell lung cancer during the last 5 years. Eur J Cancer. 2013;49(7):1555–1564.
    1. Aupérin A, Le Péchoux C, Rolland E, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol. 2010;28(13):2181–2190.
    1. Bayman N, Alam N, Faivre-Finn C. Radiotherapy for lung cancer in the elderly. Lung Cancer. 2010;68(2):129–136.
    1. Jemal A, Thun MJ, Ries LA, et al. Annual report to the nation on the status of cancer, 1975–2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst. 2008;100(23):1672–1694.
    1. Pirtoli L, Bindi M, Bellezza A, Pepi F, Tucci E. Unfavorable experience with hypofractionated radiotherapy in unresectable lung cancer. Tumori. 1992;78(5):305–310.
    1. Slotman BJ, Njo KH, de Jonge A, Meijer OW, Karim AB. Hypofractionated radiation therapy in unresectable stage III non-small cell lung cancer. Cancer. 1993;72(6):1885–1893.
    1. Vogelius IS, Westerly DC, Cannon GM, Bentzen SM. Hypofractionation does not increase radiation pneumonitis risk with modern conformal radiation delivery techniques. Acta Oncol. 2010;49(7):1052–1057.
    1. Gibbs IC, Loo BW., Jr CyberKnife stereotactic ablative radiotherapy for lung tumors. Technol Cancer Res Treat. 2010;9(6):589–596.
    1. Karam SD, Horne ZD, Hong RL, McRae D, Duhamel D, Nasr NM. Dose escalation with stereotactic body radiation therapy boost for locally advanced non small cell lung cancer. Radiat Oncol. 2013;8:179.
    1. Benedict SH, Yenice KM, Followill D, et al. Stereotactic body radiation therapy: the report of AAPM Task Group 101. Med Phys. 2010;37(8):4078–4101.
    1. Timmerman RD. Surgery versus stereotactic body radiation therapy for early-stage lung cancer: who’s down for the count? J Clin Oncol. 2010;28(6):907–909.
    1. MacManus M, Nestle U, Rosenzweig KE, et al. Use of PET and PET/CT for radiation therapy planning: IAEA expert report 2006–2007. Radiother Oncol. 2009;91(1):85–94.
    1. Machtay M, Paulus R, Moughan J, et al. Defining local-regional control and its importance in locally advanced non-small cell lung carcinoma. J Thorac Oncol. 2012;7(4):716–722.
    1. Le Chevalier T, Arriagada R, Quoix E, et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst. 1991;83(6):417–423.
    1. Kim TY, Yang SH, Lee SH, et al. A phase III randomized trial of combined chemoradiotherapy versus radiotherapy alone in locally advanced non-small-cell lung cancer. Am J Clin Oncol. 2002;25(3):238–243.
    1. Atagi S, Kawahara M, Yokoyama A, et al. Japan Clinical Oncology Group Lung Cancer Study Group Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non-small-cell lung cancer: a randomised, controlled, phase 3 trial by the Japan Clinical Oncology Group (JCOG0301) Lancet Oncol. 2012;13(7):671–678.
    1. Abratt RP, Bogart JA, Hunter A. Hypofractionated irradiation for non-small cell lung cancer. Lung Cancer. 2002;36(3):225–233.
    1. Tinnemans MM, Lenders MH, ten Velde GP, Blijham GH, Ramaekers FC, Schutte B. Prognostic value of cytokinetic parameters in lung cancer after in vivo bromodeoxyuridine labelling. Anticancer Res. 1999;19(1A):531–534.
    1. Withers HR, Taylor JM, Maciejewski B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol. 1988;27(2):131–146.
    1. van Baardwijk A, Bosmans G, Bentzen SM, et al. Radiation dose prescription for non-small-cell lung cancer according to normal tissue dose constraints: an in silico clinical trial. Int J Radiat Oncol Biol Phys. 2008;71(4):1103–1110.
    1. Partridge M, Ramos M, Sardaro A, Brada M. Dose escalation for non-small cell lung cancer: analysis and modelling of published literature. Radiother Oncol. 2011;99(1):6–11.
    1. Kepka L, Tyc-Szczepaniak D, Bujko K. Dose-per-fraction escalation of accelerated hypofractionated three-dimensional conformal radiotherapy in locally advanced non-small cell lung cancer. J Thorac Oncol. 2009;4(7):853–861.
    1. Amini A, Lin SH, Wei C, Allen P, Cox JD, Komaki R. Accelerated hypofractionated radiation therapy compared to conventionally fractionated radiation therapy for the treatment of inoperable non-small cell lung cancer. Radiat Oncol. 2012;7:33.
    1. Zhu ZF, Fan M, Wu KL, et al. A phase II trial of accelerated hypofractionated three-dimensional conformal radiation therapy in locally advanced non-small cell lung cancer. Radiother Oncol. 2011;98(3):304–308.
    1. Osti MF, Agolli L, Valeriani M, et al. Image guided hypofractionated 3-dimensional radiation therapy in patients with inoperable advanced stage non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2013;85(3):e157–e163.
    1. Salazar OM, Sandhu TS, Lattin PB, et al. Once-weekly, high-dose stereotactic body radiotherapy for lung cancer: 6-year analysis of 60 early-stage, 42 locally advanced, and 7 metastatic lung cancers. Int J Radiat Oncol Biol Phys. 2008;72(3):707–715.
    1. Bonfili P, Di Staso M, Gravina GL, et al. Hypofractioned radical radiotherapy in elderly patients with medically inoperable stage I–II non-small-cell lung cancer. Lung Cancer. 2010;67(1):81–85.
    1. Nagata Y, Matsuo Y, Takayama K, et al. Current status of stereotactic body radiotherapy for lung cancer. Int J Clin Oncol. 2007;12(1):3–7.
    1. Lv Y, Wang Z, Zhu X, et al. Preliminary effect of Cyberknife radiosurgery in the treatment of 31 patients with advanced non-small cell lung cancer. Zhongguo Fei Ai Za Zhi. 2011;14(4):329–334. Chinese.
    1. Stinchcombe TE, Bogart JA. Novel approaches of chemoradiotherapy in unresectable stage IIIA and stage IIIB non-small cell lung cancer. Oncologist. 2012;17(5):682–693.
    1. Machtay M, Duan F, Siegel BA, et al. Prediction of survival by [18F] fluorodeoxyglucose positron emission tomography in patients with locally advanced non-small-cell lung cancer undergoing definitive chemoradiation therapy: results of the ACRIN 6668/RTOG 0235 trial. J Clin Oncol. 2013;31(30):3823–3830.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever